➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Medtronic
Boehringer Ingelheim
Colorcon
Mallinckrodt

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 9,498,528

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,498,528
Title:Treatment of multiple sclerosis (MS)
Abstract: A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favorable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and .ltoreq.12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1-24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.
Inventor(s): Margolin; David H. (Somerville, MA), Hong; Walter (Whippany, NJ), Coles; Alasdair J. (Cambridge, GB), Compston; Alastair (Cambridge, GB), Shaked; Ze\'ev (San Antonio, TX)
Assignee: GENZYME CORPORATION (Cambridge, MA) ALCAFLEU MANAGEMENT GMBH & CO. KG. (Ot Waltersdorf, DE)
Application Number:11/900,211
Patent Claims:see list of patent claims

Details for Patent 9,498,528

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial GENZYME CORPORATION (Cambridge, MA) ALCAFLEU MANAGEMENT GMBH & CO. KG. (Ot Waltersdorf, DE) 2026-09-13 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial GENZYME CORPORATION (Cambridge, MA) ALCAFLEU MANAGEMENT GMBH & CO. KG. (Ot Waltersdorf, DE) 2026-09-13 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial GENZYME CORPORATION (Cambridge, MA) ALCAFLEU MANAGEMENT GMBH & CO. KG. (Ot Waltersdorf, DE) 2026-09-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKesson
Harvard Business School
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.